EXPAREL is a bupivacaine liposome injectable suspension for post surgical pain.
Pacira also reported an average of 28 new accounts ordering EXPAREL, totaling at 363 for the second quarter of 2014. 2,815 accounts have ordered EXPAREL through June 30, with 469 accounts ordering more than $100,000 worth of product since the launch.
More articles on Pacira:
4 Latest Drug Approvals
Study: EXPAREL Infiltration Effectively Controls Postsurgical Pain
Pacira Joins NPSF Coalition
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
